If you are interested in participating in or learning more about our research program, please ask your cardiologist or call 303-744-1065 and ask for the research department.
This clinical study is intended to confirm in a post-approval setting the safety and effectiveness of the Amplatzer™ PFO Occluder and Amplatzer™ Talisman PFO Occluder in patients who have had an ischemic stroke due to presumed paradoxical embolism through a patent foramen ovale.
A study to evaluate the safety and efficacy of transcatheter closure of patent foramen ovale for relief of migraine headaches.
The purpose of this clinical study is the assessment of the safety and effectiveness of the Flex II PFO Occluder in the treatment of subjects 18 years of age or older who have had a cytogenic stroke due to a presumed paradoxical embolism and the presence of a patent foramen ovale.
To generate real-world clinical evidence associated with coronary intravascular lithotripsy in a population of female subjects with calcified coronary artery disease.
This event-driven clinical study is intended to demonstrate the efficacy and safety of Milvexian, an oral factor XIa Inhibitor, after a recent coronary syndrome.
To evaluate the efficacy and safety of MK-0616, an oral PCSK9i, in reducing major adverse cardiovascular events in participants at high cardiovascular risk.
A controlled trial comparing the current SOC of continuous direct oral anticoagulant (DOAC) use versus time-delimited (1 month) DOAC guided by an atrial fibrillation sensing watch (AFSW, Apple Watch) in participants with a with a history of non-permanent Atrial Fibrillation and low-moderate stroke risk (CHA2DS2-VASc score of 1-4 for men, 2-4 for women).
To demonstrate that the VOLT Pulsed Field Ablation system is safe and effective for the treatment of symptomatic, recurrent, drug refractory paroxysmal and persistent atrial fibrillation.
The purpose of this registry is to develop valid scientific evidence of the safety and benefit of Barostim Therapy in the commercial setting in patients that were recently implanted with the Barostim System.
REAL AF Registry is an observational registry designed to obtain real-world clinical experience of paroxysmal and persistent ablation using the Biosense Webster CARTO technologies.
To demonstrate the safety and effectiveness of the Reducer system for treatment of patients with refractory angina pectoris treated with maximally tolerated guideline-directed medical therapy who demonstrate objective evidence of reversible myocardial ischemia in the distribution of the left coronary artery and who are deemed unsuitable for revascularization.
To assess the clinical efficacy of selatogrel when self-administered upon occurrence of symptoms suggestive of an acute myocardial infarction (AMI) in subjects at risk of having a recurrent AMI.